Ocugen (OCGN) said Tuesday that the Data and Safety Monitoring Board for its phase 1/2 clinical trial of CU410ST to treat Stargardt disease has approved enrollment for the trial's second phase.
Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss.
The biotech firm also said there were no serious adverse events reported for the first phase of the trial.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments